

Attendance**Members present:****Guests:****Presenters:****Minute Recorder:****Call to Order:** 5:01 pm**Approval of Minutes**

Discussion	Action
May minutes	13 Votes - accepted
Old Business: - None New Business: - None	No Discussion

New Products

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Trypyr (acoltremon) eye drop	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Emrelis (telisotuzumab vedotin-tllv) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Penpulimab-kcqx IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Avmapki Fakzynja Copak (avutometinib/defactinib) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Zevaskyn (prademagene zamikeracel) cellular sheets	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0

Imaavy (nipocalimab-aahu) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Andembry (garadacimab-gxii) SQ	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Ekterly (sebetralstat) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	██████ asked if in the clinical trial anyone was using it inappropriately given the high price point. ██████ responded that there was no mention in the trial of inappropriate use.	Must Add- 0 May Add- 13 Do Not Add- 0

Abbreviated New Products

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Arynta (lisdexamphetamine) oral solution	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Atzumi (dihydroergotamine) nasal powder	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Brekiya (dihydroergotamine mesylate) injection	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Brukinsa (Zanubrutinib) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Enflonsia (clesrovimab-cfor) injection	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Harliku (nitisinone) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Khindivi (hydrocortisone) oral solution	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Kirsty (insulin aspart-xjhz) injection	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Nuvaxovid (COVID-19 vaccine)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0

Spevigo (spesolimab-sbzo) SQ	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Starjemza (Ustekinumab-hmny)	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Tyzavan (vancomycin) IV solution	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Widaplik (telmisartan, amlodipine, indapamide) tablet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Xifyrm (meloxicam) IV	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Yeztugo (lenacapavir) tabs/injection	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Yutrepia (treprostinil) inhalation powder	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Zelvysia (sapropterin dihydrochloride) oral packet	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0
Zusduri (mitomycin) intravesical solution	☐ Must Add ☒ May Add ☐ Do Not Add	None	Must Add- 0 May Add- 13 Do Not Add- 0

New FDA Indications

Drug Name	Decision	Discussion	Vote Count
	All Lines of Business (Where applicable)		
Descovy (emtricitabine/tenofovir alafenamide)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Dupixent (dupilumab)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Fylnetra (pegfilgrastim-pbbk)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Gamifant (emapalumab-lzsg)	☒ No Change ☐ Change	None	No Change- 13 Change- 0

Jivi (antihemophilic factor [recombinant], pegylated-aucl)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Kerendia (finerenone)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Mavyret (glecaprevir and pibrentasvir)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Monjuvi (tafasitamab)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Nityr (nitisinone)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Nubeqa (darolutamide)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Nucala (mepolizumab)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Opdivo (nivolumab)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Releuko (filgrastim-ayow)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Riabni (rituximab-arrx)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Rinvoq (upadacitinib)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Ruxience (rituximab-pvvr)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Susvimo (ranibizumab)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Truxima (rituximab-abbs)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Tybost (cobicistat)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Welireg (belzutifan)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Yervoy (ipilimumab)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Zejula (niraparib)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Zoryve (roflumilast)	☒ No Change ☐ Change	None	No Change- 13 Change- 0
Zynyz (retifanlimab-dlwr)	☒ No Change ☐ Change	None	No Change- 13 Change- 0

DURs	
	Discussion
PA Medicaid	None

Formulary Review & Revisions				
PA Medicaid				
Drug Name	Recommendation	Decision	Discussion	Vote Count
Additions: Paxlovid 150/100mg pack (low dose for renal impairment)	No change	Agreed	None	13

Policies			
PA Medicaid			
Policy Name	New/Revision	Decision (vote is for all policies)	Discussion
Hemophilia tissue factor pathway inhibitor (TFPI) antagonists Imcivree Journavx Vanrafia Vykat XR	☒ New Policy ☐ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None

Brineura Bylvay CAR-T immunotherapy Complement Inhibitors Corticotropin Cough and cold medication in children less than 4 Crysvisa Cystic fibrosis biologic response modifiers Daraprim Duvyzat Enspryng Formulary Management Gene Therapy Agents Givlaari Joenja Lantidra Livmarli Luxturna Phenylketonuria Medications Pulmozyme Rezdiffra Sandostatin LAR Selective transthyretin (TTR) stabilizers Skyclarys Somatuline Depot SMA Medications Sucraid SLE Agents Tzield Xialflex Zuruvac	☐ New Policy ☒ Policy Revision	☒ Approve as Written ☐ Do Not Approve as Written	None
PA Medicaid Operational Policies			
Formulary Management Oncology Medication Prior Auth Process Review Prior Authorization of Drugs	☐ New Policy ☒ Policy Revisions	☒ Approve as Written ☐ Do Not Approve as Written	None

Final Discussion
None
Next Meeting Date: November 6, 2025
Time Meeting Adjourned: 5:31pm

Respectfully Submitted:

[Redacted Signature]

Date: 8/7/2025

CONFIDENTIAL